October 7, 2021 -- Century Therapeutics and Outpace Bio have entered into a research collaboration on CAR engineering.
Century develops induced pluripotent stem cell (iPSC)-derived NK and T-cell therapies to help treat hematologic and solid tumor malignancies with significant unmet medical need.
Under terms of the agreement, Century will explore Outpace's protein solutions for cell therapy to enhance the functionality of its iPSC platform. The collaboration will initially focus on hematologic malignancies, with an option to expand to additional candidates, according to the companies.
The collaboration brings together Century's CAR and protein engineering expertise with Outpace's protein design and synthetic biology capabilities. The goal is to enhance CAR functionality by combining Outpace's optimized CAR spacer technology with Century's VHH domain binders.